Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.
We prospectively evaluated 28 triple-class experienced HIV-1-infected patients harbouring R5 virus, who received maraviroc, raltegravir and etravirine. By on-treatment analysis, 26 (92%) had less than 50 copies HIV-RNA/ml at week 48. The median (interquartile range) 48-week increase in CD4 cell counts was 267 (136-355) cells/microl. Three serious adverse events occurred: one recurrence of mycobacterial spondylodiscitis, one anal cancer, one Hodgkin lymphoma. Although long-term safety needs further study, this protease inhibitor and nucleoside analogue-sparing regimen showed sustained efficacy.
Department of Infectious Diseases, San Raffaele Scientific Institute, Italy. silvia.nozza@hsr.it
Silvia
S
Nozza
Laura
L
Galli
Francesca
F
Visco
Alessandro
A
Soria
Filippo
F
Canducci
Stefania
S
Salpietro
Nicola
N
Gianotti
Alba
A
Bigoloni
Liviana Della
LD
Torre
Giuseppe
G
Tambussi
Adriano
A
Lazzarin
Antonella
A
Castagna
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D003510:Cyclohexanes / Q000008:administration & dosage*; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D009570:Nitriles; D011724:Pyridazines / Q000008:administration & dosage*; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage*; D016879:Salvage Therapy; D014230:Triazoles / Q000008:administration & dosage*; D019562:Viral Load
D003510:Cyclohexanes; D017320:HIV Protease Inhibitors; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; D014230:Triazoles; C451734:etravirine; D000077592:Maraviroc